BACKGROUND: Following bariatric surgery, increasing physical activity (PA) level helps to maintain weight loss and has benefits on quality of life. Although, one could believe that the weight loss achieved with the surgery would ease patients to engage in more PA practices, the PA habits of these patients are not known. Evidences and objectives measures of the PA level are sparse in the literature in this population. We measured the evolution of PA level in severely obese patients who underwent bariatric surgery. METHODS AND RESULTS: Forty-seven severely obese patients from the randomized controlled trial ACTIVE were either assigned in the supervised exercise group (ExG ¼ 32) or control group (CG ¼ 15) . Anthropometric measurements and daily PA using an accelerometer were performed before, at 3, 6 and 12 months after bariatric surgery. The ExG trained 3 times a week for 60 minutes during 12 weeks between the 3rd and 6th months. At baseline and 3 months, both groups were comparable regarding anthropometric measurements (p>0.05). After 6 months, participants in CG and ExG had lost 13.1AE5.6 vs. 14.2AE5.5kg; p¼0.509 respectively with approximately similar changes between 6 and 12 months. Regarding PA parameters at baseline, participants in the CG were spending 11.3AE2.4 hours doing sedentary behavior and averaging 5001AE2525 steps per day. For the ExG, 12.0AE2.1 hours were devoted to sedentary behavior with a total of 4711AE2183 daily steps. Daily time spent at moderate intensity PA was 16.7AE18.4 vs. 19.4AE39.9min; p¼0.968 for CG and ExG respectively. Between 3 and 6 months, both groups had decreased their time spent at sedentary behavior (CG ¼ -1.5AE2.3 hours and ExG ¼ -0.3AE2.4 hours; p¼0.718), increased their number of daily steps (CG ¼ 1215AE2324 steps and ExG ¼ 1303AE2522 steps; p¼0.717) and their time spent at moderate intensity PA (CG ¼ 19.0AE15.6 min and ExG ¼ 8.6AE24.5 min; p¼0,085) with no significant difference between groups. At 12 months follow-up, no significant changes occurred in PA parameters. CONCLUSION: According to these results, anthropometric measurements and PA levels are not affected by the PA intervention. This suggests that a supervised exercise training program does not seem to play a major role in the patients' daily PA behaviors.
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QUANTITATIVE PROFILING OF OXYLIPINS IN PATIENTS PRESENTING WITH ST ELEVATION MYOCARDIAL INFARCTION (STEMI) Z Solati, A Surendran, H Aukema, A Ravandi
Winnipeg, Manitoba BACKGROUND: Previous studies have shown that there is persistent oxidative stress after myocardial infarction (MI) and percutaneous coronary intervention (PCI). Oxylipins are lipid oxidation products that can be generated mainly by enzymatic oxidation through cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (CYP P450) pathways. The aim of this study was to profiling oxylipins before and in various time points after PCI in STEMI patients. METHODS AND RESULTS: Blood samples were collected from subjects with STEMI (n¼17) at five time points including prior to PCI (time point 1), and 2h (time point 2), 24h (time point 3), 48h (time point 4) and 30 day (time point 5) following PCI. As controls, blood samples were also collected from subjects (n¼20) with non-obstructive coronary artery disease after diagnostic angiography. Oxylipins identification and quantification were performed using high-performance electrospray mass spectrometry and dueterated internal standards. Seventy six oxylipins were identified in STEMI patients which were derived from LOX and CYP pathways and nonenzymatic oxidation. No COX derived oxylipins were identified in patients. The average levels of total oxylipins were 0.08 AE 0.04 and 0.05AE0.02 ng/ul of plasma of STEMI patients and controls, respectively. Oxylipins that derived from arachidonic acid (AA) were the most abundant oxylipins in STEMI patients which constituted about 60% of all identified/quantified oxylipins. Oxylipins derived from linoleic acid (LA) were the second most abundant oxylipins which accounted for 28% of all identified/quantified oxylipins in STEMI patients. 20-carboxy-arachidonic acid (20-COOH-AA), which is a metabolite of 20-hydroxyeicosatetraenoic acid (20-HETE) and derived from AA, along with 9-HODE and 12-HODE, which derived from LA, were three most abundant oxylipins in all STEMI groups. One way ANOVA analysis showed that the levels of oxylipins derived from LOX pathway decreased significantly at 24h and 48h after PCI (time point-3 and 4) compared with pre and post PCI (Time point-1, 2). Further analysis revealed that 5-HETE and 9-HODE, were the two LOX derived oxylipins that decreased significantly in this group of oxylipins (p < 0.05). However, other oxylipins derived from CYP pathway or non-enzematic oxidation did not differ significantly between STEMI groups. At 30 day following PCI, levels of oxylipins slightly increased, although it was not significant. CONCLUSION: This is the first study to determine the oxylipin profile in STEMI patients. As these compounds have potent cardiovascular activities, our data may guide future therapeutics that aim to modulate oxylipins after MI.
SERUM SCLEROSTIN AND ADVERSE OUTCOMES IN ELDERLY PATIENTS WITH STABLE CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION W He, C Li, Q Chen
Chongqing, China BACKGROUND: Recently, sclerostin, a bone-derived protein, has been shown to play a key role in the progression of atherosclerosis. However, few studies have investigated the influence of sclerostin on the prognosis of cardiovascular disease. We investigated the relationship between serum sclerostin levels and adverse outcomes in elderly patients with stable coronary artery disease (SCAD) who are undergoing percutaneous coronary intervention (PCI). METHODS AND RESULTS: A total of 310 elderly SCAD patients who underwent PCI were enrolled in this study, with a follow-up of 3 years. According to the median serum sclerostin levels, subjects were stratified into a low sclerostin (low scl) group (n¼144) and a high sclerostin (high scl) group (n¼166). Time-to-event analyses were performed by the Kaplan-Meier method. The associations between sclerostin levels and main the adverse cardiovascular and cerebrovascular events (MACCEs) and mortality were evaluated by Cox multivariate regression analysis. Kaplan-Meier curves showed that the high scl group had a significantly higher MACCE-free rate (log rank p < 0.001) and better survival (log rank both p < 0.05) than the low scl group did. Serum sclerostin was an independent predictor of MACCEs and all-cause mortality. In addition, serum sclerostin levels were significantly associated with N-MID (b¼-0.357, p < 0.001), b-CTX (b¼0.200, p¼0.012), and PINP (b¼0.207, p¼0.006) levels, a lower presence of multivessel disease (b¼-0.223, p¼0.005) and lower CCS angina class (b¼-0.160, p¼0.017). CONCLUSION: Serum sclerostin is a prognostic parameter for predicting and intervening in the adverse outcomes of elderly SCAD patients undergoing PCI, which may be explained by its potential role in the bone-vascular axis.
CORONARY ARTERY DISEASE IN ADULTS UNDERGOING TRANSCATHETER PATENT FORAMEN OVALE CLOSURE FOLLOWING CRYPTOGENIC STROKE
C Frankfurter, A Muthuppalaniappan, R Gorocica-Romero, L Abrahamyan, C Olesovsky, M Osten, L Benson, E Horlick Oakville, Ontario BACKGROUND: Patent foramen ovale (PFO) is identified in almost one half of patients with cryptogenic stroke. There are presently no universally-established indications for the screening of adults for coronary artery disease (CAD) at the time of transcatheter PFO closure. The presence of subclinical CAD may be of interest in adults who have suffered a cryptogenic stroke in the context of a PFO. METHODS AND RESULTS: Consecutive patients over 40 years of age who underwent PFO transcatheter closure with routine coronary angiography at an academic quaternary center from 2009 to 2017 were retrospectively analyzed. Patients included had no prior history of CAD and were diagnosed with a PFO
